Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Louisiana Cimzia Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - LouisianaPolicy MA-168

    Certolizumab pegol (Cimzia) coverage

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy MA-168 alerts

    Get alerted when Policy MA-168 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Medicare Advantage policy governs medical-benefit authorization and coverage of lyophilized single-dose-vial certolizumab pegol (Cimzia) for adults with Crohn's disease, rheumatoid arthritis, or psoriatic arthritis. Coverage requires contract benefits, medical-necessity criteria, and compliance with the applicable diagnosis-specific initial or continuation requirements.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Louisiana
    PolicyCertolizumab pegol (Cimzia) coverage
    Policy CodePolicy MA-168
    Change TypeNo material change
    Effective DateJan 1, 202743d
    Last ReviewOct 20, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests under the medical benefit for the lyophilized single-dose vial and document applicable diagnosis-specific medical-necessity criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Covered clinical indications
    18+Minimum adult age
    NegativePretreatment TB test
    Medical onlyBenefit channel
    400 mgMaximum common induction dose

    General Coverage Requirements

    General Coverage Requirements

    Coverage for eligible medical treatments, procedures, drugs, devices, or biological products is provided only when ALL of the following are met:

    ALL of the following

    • Benefits are available in the member's contract or certificate.
    • Medical necessity criteria and guidelines are met.

    Initial Therapy — Crohn's Disease

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient is 18 years of age or older.
    • Patient has moderately to severely active Crohn's disease.
    • Patient has failed treatment with conventional therapies such as corticosteroids, 6-mercaptopurine (6-MP), and azathioprine, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
    • The requested drug is NOT used in combination with other biologic disease-modifying antirheumatic drugs (DMARDs), such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
    • Patient has a negative tuberculosis (TB) test, such as a purified protein derivative (PPD) or blood test, before treatment.
    • The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 400 mg every four weeks.

    Continuation Therapy — Crohn's Disease

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
    • Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by improvement in objective measures such as fecal or serum inflammatory markers, endoscopic findings, or reduced corticosteroid use, or in symptoms such as pain, fatigue, stool frequency, or blood in stool.
    • The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 400 mg every four weeks.
    • The requested drug is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).

    Initial Therapy — Rheumatoid Arthritis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient is 18 years of age or older.
    • Patient has moderately to severely active rheumatoid arthritis.
    • Patient has failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
    • Patient has a negative TB test, such as a PPD or blood test, before treatment.

    Continuation Therapy — Rheumatoid Arthritis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
    • Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths.
    • The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week; a maintenance dose of 400 mg every 4 weeks can also be considered.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).

    Initial Therapy — Psoriatic Arthritis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient is 18 years of age or older.
    • Patient has active psoriatic arthritis.
    • Patient has failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
    • Patient has a negative TB test, such as a PPD or blood test, before treatment.

    Continuation Therapy — Psoriatic Arthritis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
    • Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths.
    • The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week; a maintenance dose of 400 mg every 4 weeks can also be considered.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).

    Initial Therapy — Ankylosing Spondylitis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient is 18 years of age or older.
    • Patient has active ankylosing spondylitis.
    • Patient has failed treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
    • Patient has a negative TB test, such as a PPD or blood test, before treatment.

    Continuation Therapy — Ankylosing Spondylitis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
    • Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by improvement in objective measures such as ASDAS, BASDAI, or inflammatory serum markers, or by reduced pain, stiffness, or improved daily functioning.
    • The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).

    Initial Therapy — Plaque Psoriasis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient is 18 years of age or older.
    • Patient has moderate to severe plaque psoriasis.
    • Patient is a candidate for phototherapy or systemic therapy.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
    • Patient has a negative TB test, such as a PPD or blood test, before treatment.

    Continuation Therapy — Plaque Psoriasis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
    • Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by reduced estimated body surface area affected by psoriasis, decreased erythema, induration/thickness, or scaling, and/or improvement in pain, itching, or burning.
    • The requested dose is no higher than 400 mg every other week.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).

    Initial Therapy — Non-radiographic Axial Spondyloarthritis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has active non-radiographic axial spondyloarthritis confirmed by the presence of sacroiliitis on magnetic resonance imaging (MRI).
    • Patient has failed at least TWO months of current continuous therapy with at least TWO different oral NSAIDs at prescription-strength dosages, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
    • Patient is 18 years of age or older.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
    • Patient has a negative TB test, such as a PPD or blood test, before treatment.

    Continuation Therapy — Non-radiographic Axial Spondyloarthritis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
    • Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by improvement in objective measures such as ASDAS, BASDAI, or inflammatory serum markers, or by reduced pain, stiffness, or improved daily functioning.
    • The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).

    Initial Therapy — Polyarticular Juvenile Idiopathic Arthritis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient has a diagnosis of active polyarticular juvenile idiopathic arthritis.
    • Patient has failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests these products will be ineffective or cause an adverse reaction.
    • Cimzia is NOT used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or other drugs such as apremilast (Otezla) or tofacitinib (Xeljanz/XR).
    • Patient has a negative TB test, such as a PPD or blood test, before treatment.

    Initial Therapy — Polyarticular Juvenile Idiopathic Arthritis: Applicable Dosing Options

    The patient must meet ONE of the following weight-based dosing options:

    ONE of the following

    • For patients weighing 10 kg to less than 20 kg, the requested dose is no higher than 100 mg at weeks 0, 2, and 4, followed by 50 mg every 2 weeks.
    • For patients weighing 20 kg to less than 40 kg, the requested dose is no higher than 200 mg at weeks 0, 2, and 4, followed by 100 mg every 2 weeks.
    • For patients weighing greater than or equal to 40 kg, the requested dose is no higher than 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks.

    Continuation Therapy — Polyarticular Juvenile Idiopathic Arthritis

    Continuation coverage requires the applicable criteria below:

    ALL of the following

    • Patient has received an initial authorization for Cimzia from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan.
    • Patient has experienced a beneficial clinical response from baseline before Cimzia, evidenced by improved range of motion, reduced joint pain or tenderness, decreased duration of morning stiffness or fatigue, improved function or activities of daily living, reduced corticosteroid dosage, or improvement in inflammatory serum markers.
    • ONE of the following weight-based dosing options

      • For patients weighing 10 kg to less than 20 kg, the requested dose is no higher than 100 mg at weeks 0, 2, and 4, followed by 50 mg every 2 weeks.
      • For patients weighing 20 kg to less than 40 kg, the requested dose is no higher than 200 mg at weeks 0, 2, and 4, followed by 100 mg every 2 weeks.

    Authorization, if granted, is for the lyophilized single-dose vial only. It does not apply to the non-lyophilized prefilled syringe. If authorization is granted, it applies only to the medical benefit.

    Cimzia must not be used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or with apremilast (Otezla) or tofacitinib (Xeljanz/XR), where prohibited by the applicable indication criteria.

    Blue Advantage does not cover investigational or experimental services, including any drug, device, procedure, or service provided under the investigational arm of a clinical trial or study, unless mandated by the Centers for Medicare and Medicaid Services. Coverage is limited to routine services for Category A IDE studies and devices and related services for Category B IDE studies when not supplied by the trial sponsor. Approved IDE studies are posted on www.cms.gov/medicare/coverage/evidence.

    Cimzia must not be used in combination with other biologic DMARDs, such as adalimumab (Humira, biosimilars) or etanercept (Enbrel), or with apremilast (Otezla) or tofacitinib (Xeljanz/XR), where prohibited by the applicable indication criteria.

    Coverage is not available for investigational medical treatments or procedures, drugs, devices, or biological products. Use of Cimzia for indications or dosages other than those listed in this policy is considered investigational, as is use when patient-selection criteria are not met, except where specifically identified as not medically necessary.

    Use of Cimzia is considered not medically necessary when the applicable disease-specific patient-selection criteria are not met, including the required treatment failures or restrictions for rheumatoid arthritis, psoriatic arthritis, active ankylosing spondylitis, moderate to severe plaque psoriasis, active non-radiographic axial spondyloarthritis, and polyarticular juvenile idiopathic arthritis.

    For rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis, the patient must have failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests those products will be ineffective or cause an adverse reaction.

    For active ankylosing spondylitis, the patient must have failed treatment with NSAIDs unless clinical evidence or patient history suggests those products will be ineffective or cause an adverse reaction.

    For moderate to severe plaque psoriasis, the patient must have greater than 10% of body surface area affected, or 10% or less with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function, such as the palms, soles of the feet, head/neck, or genitalia.

    For plaque psoriasis, the patient must have failed to respond to an adequate trial of UVB, PUVA, or systemic therapy such as methotrexate, cyclosporine, or acitretin.

    For active non-radiographic axial spondyloarthritis, the patient must have failed at least TWO months of current continuous therapy with at least TWO different oral NSAIDs at prescription-strength dosages.

    For polyarticular juvenile idiopathic arthritis, the patient must have failed treatment with one or more traditional DMARDs, such as methotrexate, unless clinical evidence or patient history suggests those products will be ineffective or cause an adverse reaction.

    Continued use of Cimzia is considered not medically necessary when the patient has not experienced a beneficial clinical response from baseline before Cimzia.

    Initial Therapy by Indication

    Crohn's Disease Initial Therapy

    Covered when ALL of the following are met:

    Crohn's disease initial therapy: The patient is an adult with moderately to severely active Crohn's disease; has failed specified conventional therapies unless ineffective or unsafe; is not receiving prohibited combination therapy; has a negative pretreatment TB test; and the requested dose is within the policy limit.400 mg initially and at weeks 2 and 4, then 400 mg every 4 weeks

    Rheumatoid Arthritis Initial Therapy

    Covered when ALL of the following are met:

    Rheumatoid arthritis initial therapy: The patient is an adult with moderately to severely active rheumatoid arthritis; has failed one or more traditional DMARDs unless ineffective or unsafe; is not receiving prohibited combination therapy; has a negative pretreatment TB test; and the requested dose is within the policy limit.400 mg initially and at weeks 2 and 4, then 200 mg every other week or 400 mg every 4 weeks

    Continuation Therapy by Indication

    Crohn's Disease Continuation

    Covered when ALL of the following are met:

    Crohn's disease continuation: The patient has an initial plan authorization or transferred active-course authorization; has demonstrated beneficial clinical response from baseline; the requested dose is within the allowed schedule; and Cimzia is not used with other biologic DMARDs, apremilast, or tofacitinib.400 mg initially and at weeks 2 and 4, then 400 mg every 4 weeks

    Rheumatoid Arthritis Continuation

    Covered when ALL of the following are met:

    Rheumatoid arthritis continuation: The patient has an initial plan authorization or transferred active-course authorization; has demonstrated beneficial clinical response from baseline; the requested dose is within the allowed schedule; and Cimzia is not used with other biologic DMARDs, apremilast, or tofacitinib.400 mg initially and at weeks 2 and 4, then 200 mg every other week or 400 mg every 4 weeks

    Required Prior Treatment

    Coverage requirementRequired prior therapyTiming / exception
    Required before initial Cimzia coverageConventional therapies, such as corticosteroids, 6-mercaptopurine, and azathioprineTreatment failure is required unless clinical evidence or patient history indicates ineffectiveness or an adverse reaction
    Coverage requirementRequired prior therapyTiming / exception
    Required before initial Cimzia coverageOne or more traditional DMARDs, such as methotrexateTreatment failure is required unless clinical evidence or patient history indicates ineffectiveness or an adverse reaction; applies to rheumatoid arthritis and psoriatic arthritis
    Coverage requirementRequired prior therapyTiming / exception
    Required before initial Cimzia coverage for active psoriatic arthritisOne or more traditional DMARDs, such as methotrexateTreatment failure is required unless clinical evidence or patient history indicates ineffectiveness or an adverse reaction
    Coverage requirementRequired prior therapyTiming / exception
    Required before initial Cimzia coverage for active ankylosing spondylitisNonsteroidal anti-inflammatory drugs (NSAIDs)Treatment failure is required unless clinical evidence or patient history indicates ineffectiveness or an adverse reaction
    Coverage requirementQualifying prior therapyTiming / exception
    One qualifying modality required before initial Cimzia coverage for plaque psoriasisUltraviolet B; psoralen plus ultraviolet A; or systemic therapy such as methotrexate, cyclosporine, or acitretinFailure to respond to an adequate trial is required unless clinical evidence or patient history indicates ineffectiveness or an adverse reaction
    Coverage requirementRequired prior therapyDuration and exception
    Required before initial Cimzia coverage for non-radiographic axial spondyloarthritisAt least two different oral NSAIDs at prescription-strength dosagesAt least 2 months of current continuous therapy; exception applies when clinical evidence or patient history indicates ineffectiveness or an adverse reaction
    Coverage requirementRequired prior therapyTiming / exception
    Required before initial Cimzia coverage for polyarticular juvenile idiopathic arthritisOne or more traditional DMARDs, such as methotrexateTreatment failure is required unless clinical evidence or patient history indicates ineffectiveness or an adverse reaction
    Coverage requirementRequired prior therapyTiming / exception
    Required before initial Cimzia coverage for active polyarticular juvenile idiopathic arthritisOne or more traditional DMARDs, such as methotrexateTreatment failure is required unless clinical evidence or patient history indicates ineffectiveness or an adverse reaction
    Coverage requirementRequired prior therapyDuration
    Two oral NSAID trials required for the applicable disease criterionAt least two different oral NSAIDs at prescription-strength dosagesAt least 2 months of current continuous therapy
    Coverage requirementQualifying prior therapyTiming / exception
    Phototherapy or systemic-therapy trial required for the applicable disease criterionUltraviolet B; psoralen plus ultraviolet A; or systemic therapy such as methotrexate, cyclosporine, or acitretinFailure to respond to an adequate trial is required

    Dosing and Quantity Limits

    Crohn's disease
    Induction400 mg initially and at weeks 2 and 4
    Maintenance400 mg every 4 weeks
    Coverage dosing limitThe requested dose is no higher than the induction and maintenance schedule above
    Rheumatoid arthritis and psoriatic arthritis
    Induction400 mg initially and at weeks 2 and 4
    Standard maintenance200 mg every other week
    Alternative maintenance400 mg every 4 weeks can also be considered

    Coding and Clinical Thresholds

    CPTCPT
    No codesNo CPT codes
    HCPCSHCPCS
    J0717Certolizumab pegol
    ICD-10 DiagnosisICD-10
    All related diagnosesAll related diagnoses
    Plaque psoriasis disease extent
    Primary extent criterionGreater than 10% of body surface area
    Alternative extent criterion10% or less body surface area involving sensitive areas or areas that significantly affect daily function
    Examples of qualifying areasPalms, soles of feet, head/neck, or genitalia
    NSAID treatment trial
    Treatment durationAt least 2 months of continuous therapy
    Number of agentsAt least 2 different oral NSAIDs

    Authorization and Documentation Requirements

    Prior Authorization

    Medical-Benefit Prior Authorization

    Submit a prior authorization request for certolizumab pegol (Cimzia) only when the member's contract provides the applicable benefit and all medical-necessity criteria are met.

    • Coverage is subject to the member's benefit contract.
    • Medical-necessity criteria and guidelines must be satisfied.
    Prior Authorization

    Prior Authorization Continuity

    For continuation therapy, document either the plan's initial Cimzia authorization or an active transferred course of treatment authorized by the previous health plan.

    • Blue Advantage may honor a previous plan's authorization for the same service under the same type of in-network benefit for a 90-day transition period after a health-plan change.
    • The member or provider must submit documentation of the previous authorization.
    • The ongoing treatment must otherwise be a covered service under the Blue Advantage plan.

    Clinical Background

    Certolizumab pegol (Cimzia) is considered for adults with moderately to severely active Crohn's disease, moderately to severely active rheumatoid arthritis, or active psoriatic arthritis. The policy also addresses active ankylosing spondylitis, moderate-to-severe plaque psoriasis, active non-radiographic axial spondyloarthritis, and active polyarticular juvenile idiopathic arthritis. Initial treatment generally requires a pretreatment negative TB test, compliance with indication-specific selection criteria, and dosing within the applicable limits; continuation requires documented clinical benefit.

    Terms and Clinical Definitions

    Non-radiographic axial spondyloarthritis with MRI-confirmed sacroiliitis
    Disease typeInflammatory arthritis of the spine
    Radiographic findingNot evident on plain radiography
    Required confirmationActive sacroiliac-joint inflammation demonstrated by MRI, or sacroiliitis confirmed by MRI
    Cimzia
    Generic nameCertolizumab pegol
    Brand nameCimzia
    Drug classTumor necrosis factor (TNF) blocker

    Administration Requirements

    Billing Rule

    Administer lyophilized Cimzia in the office

    The lyophilized powder must be prepared and administered by a healthcare professional. Doses below 200 mg require administration by a healthcare professional using the vial kit.

    Policy Summary
    PayerBlue Cross Blue Shield - Louisiana
    PolicyCertolizumab pegol (Cimzia) coverage
    Policy CodePolicy MA-168
    Change TypeNo material change
    Effective DateJan 1, 202743d
    Last ReviewOct 20, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests under the medical benefit for the lyophilized single-dose vial and document applicable diagnosis-specific medical-necessity criteria.
    SourceLink
    On This Page
    General Coverage RequirementsInitial Therapy by IndicationContinuation Therapy by IndicationRequired Prior TreatmentDosing and Quantity LimitsCoding and Clinical ThresholdsAuthorization and Documentation RequirementsClinical BackgroundTerms and Clinical DefinitionsAdministration Requirements
    The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week; a maintenance dose of 400 mg every 4 weeks can also be considered.
    The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week; a maintenance dose of 400 mg every 4 weeks can also be considered.
    The requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks.
    Patient has greater than 10% of body surface area affected, or 10% or less with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function, such as the palms, soles of the feet, head/neck, or genitalia.
  1. ONE of the following treatment failures

    • Patient has failed to respond to an adequate trial of ultraviolet B (UVB).
    • Patient has failed to respond to an adequate trial of psoralen plus ultraviolet A (PUVA).
    • Patient has failed to respond to an adequate trial of systemic therapy, such as methotrexate, cyclosporine, or acitretin.
  2. The requested dose is no higher than 400 mg every other week.
  3. For lyophilized single-dose vial requests ONLY, the requested dose is no higher than 400 mg initially and at weeks 2 and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks.
  4. For patients weighing greater than or equal to 40 kg, the requested dose is no higher than 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks.
  5. Psoriatic Arthritis Initial Therapy

    Covered when ALL of the following are met:

    Psoriatic arthritis initial therapy: The patient is an adult with active psoriatic arthritis; has failed one or more traditional DMARDs unless ineffective or unsafe; is not receiving prohibited combination therapy; has a negative pretreatment TB test; and the requested dose is within the policy limit.400 mg initially and at weeks 2 and 4, then 200 mg every other week or 400 mg every 4 weeks

    Psoriatic Arthritis — Initial Coverage

    Covered when ALL of the following are met:

    Psoriatic arthritis initial coverage: The patient is at least 18 years old; has active psoriatic arthritis; has failed one or more traditional DMARDs unless ineffective treatment or adverse reaction is supported; has a negative TB test before treatment; Cimzia is not used with another biologic DMARD, apremilast, or tofacitinib; and the requested dose is within the policy limit.Induction <=400 mg at weeks 0, 2, and 4; maintenance 200 mg every other week or 400 mg every 4 weeks

    Ankylosing Spondylitis — Initial Coverage

    Covered when ALL of the following are met:

    Ankylosing spondylitis initial coverage: The patient is at least 18 years old; has active ankylosing spondylitis; has failed NSAIDs unless ineffective treatment or adverse reaction is supported; has a negative TB test before treatment; Cimzia is not used with another biologic DMARD, apremilast, or tofacitinib; and the requested dose is within the policy limit.Induction <=400 mg at weeks 0, 2, and 4; maintenance 200 mg every 2 weeks or 400 mg every 4 weeks

    Plaque Psoriasis — Initial Coverage

    Covered when ALL of the following are met:

    Plaque psoriasis initial coverage: The patient is at least 18 years old; has moderate-to-severe plaque psoriasis; is a candidate for phototherapy or systemic therapy; has greater than 10% body surface area involved or 10% or less involvement affecting sensitive or functionally significant areas; has failed an adequate trial of ultraviolet B, psoralen plus ultraviolet A, or systemic therapy unless ineffective or adverse reaction is supported; has a negative TB test; is not receiving prohibited combination therapy; and the requested dose is within the policy limit.>10% body surface area, or <=10% involving sensitive/functionally significant areas; dose <=400 mg every other week

    Non-radiographic Axial Spondyloarthritis — Initial Coverage

    Covered when ALL of the following are met:

    Non-radiographic axial spondyloarthritis initial coverage: The patient has active non-radiographic axial spondyloarthritis with MRI-confirmed sacroiliitis; has failed at least 2 months of continuous prescription-strength therapy with at least 2 different oral NSAIDs unless ineffective or adverse reaction is supported; is at least 18 years old; has a negative TB test; is not receiving prohibited combination therapy; and, for lyophilized single-dose vial requests only, the requested dose is within the policy limit.At least 2 months with 2 different oral NSAIDs; age >=18; vial induction and maintenance dose limits

    Polyarticular Juvenile Idiopathic Arthritis — Initial Coverage

    Covered when ALL of the following are met, including ONE applicable weight-based dosing option:

    Polyarticular juvenile idiopathic arthritis initial coverage

    • ONE weight-based dosing option

      • 10 kg to less than 20 kg: 100 mg at weeks 0, 2, and 4, followed by 50 mg every 2 weeks.10 kg to <20 kg
      • 20 kg to less than 40 kg: 200 mg at weeks 0, 2, and 4, followed by 100 mg every 2 weeks.20 kg to <40 kg
      • At least 40 kg: 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks.>=40 kg

    Polyarticular Juvenile Idiopathic Arthritis — Clinical Conditions and Weight Option

    ALL listed clinical conditions and ONE applicable weight-based dosing option are required:

    Clinical conditions and weight-based dose

    • ONE weight-based dosing option

      • For 10 kg to less than 20 kg: dose no higher than 100 mg at weeks 0, 2, and 4, followed by 50 mg every 2 weeks.
      • For 20 kg to less than 40 kg: dose no higher than 200 mg at weeks 0, 2, and 4, followed by 100 mg every 2 weeks.
      • For at least 40 kg: dose no higher than 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks.

    Psoriatic Arthritis Continuation

    Covered when ALL of the following are met:

    Psoriatic arthritis continuation: The patient has an initial plan authorization or transferred active-course authorization; has demonstrated beneficial clinical response from baseline; the requested dose is within the allowed schedule; and Cimzia is not used with other biologic DMARDs, apremilast, or tofacitinib.400 mg initially and at weeks 2 and 4, then 200 mg every other week or 400 mg every 4 weeks

    Psoriatic Arthritis — Continuation Coverage

    Covered when ALL of the following are met:

    Psoriatic arthritis continuation coverage: The patient has plan authorization or documented active-course authorization from a previous health plan; has demonstrated beneficial clinical response from baseline; the requested dose remains within the specified limit; and Cimzia is not used with another biologic DMARD, apremilast, or tofacitinib.Induction <=400 mg at weeks 0, 2, and 4; maintenance 200 mg every other week or 400 mg every 4 weeks

    Ankylosing Spondylitis — Continuation Coverage

    Covered when ALL of the following are met:

    Ankylosing spondylitis continuation coverage: The patient has plan authorization or documented active-course authorization from a previous health plan; has demonstrated beneficial clinical response from baseline through objective measures or improvement in pain, stiffness, or daily functioning; the requested dose remains within the specified limit; and Cimzia is not used with another biologic DMARD, apremilast, or tofacitinib.Induction <=400 mg at weeks 0, 2, and 4; maintenance 200 mg every 2 weeks or 400 mg every 4 weeks

    Plaque Psoriasis — Continuation Coverage

    Covered when ALL of the following are met:

    Plaque psoriasis continuation coverage: The patient has plan authorization or documented active-course authorization from a previous health plan; has demonstrated beneficial clinical response from baseline, including reduced body surface area, erythema, induration or thickness, scaling, pain, itching, or burning; the requested dose is no higher than 400 mg every other week; and Cimzia is not used with another biologic DMARD, apremilast, or tofacitinib.Dose <=400 mg every other week

    Non-radiographic Axial Spondyloarthritis — Continuation Coverage

    Covered when ALL of the following are met:

    Non-radiographic axial spondyloarthritis continuation coverage: The patient has plan authorization or documented active-course authorization from a previous health plan; has demonstrated beneficial clinical response from baseline through objective measures or improvement in pain, stiffness, or daily functioning; the requested dose remains within the specified limit; and Cimzia is not used with another biologic DMARD, apremilast, or tofacitinib.Induction <=400 mg at weeks 0, 2, and 4; maintenance 200 mg every 2 weeks or 400 mg every 4 weeks

    Polyarticular Juvenile Idiopathic Arthritis Continuation — Authorization, Response, and Dosing Criteria

    Covered when ALL of the following are met, including ONE applicable weight-based dosing option:

    Polyarticular juvenile idiopathic arthritis continuation

    • ONE weight-based dosing option

      • 10 kg to less than 20 kg: Dose no higher than 100 mg at weeks 0, 2, and 4, followed by 50 mg every 2 weeks.10 kg to <20 kg
      • 20 kg to less than 40 kg: Dose no higher than 200 mg at weeks 0, 2, and 4, followed by 100 mg every 2 weeks.20 kg to <40 kg
      • At least 40 kg: Dose no higher than 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks.>=40 kg
    Psoriatic arthritis
    Induction400 mg initially and at weeks 2 and 4
    Standard maintenance200 mg every other week
    Alternative maintenance400 mg every 4 weeks can also be considered
    Ankylosing spondylitis and non-radiographic axial spondyloarthritis
    Induction400 mg initially and at weeks 2 and 4
    Maintenance option 1200 mg every 2 weeks
    Maintenance option 2400 mg every 4 weeks
    Plaque psoriasis
    Maximum doseNo higher than 400 mg every other week
    Induction schedule400 mg initially and at weeks 2 and 4
    Maintenance intervalEvery other week
    Polyarticular juvenile idiopathic arthritis
    10 kg to less than 20 kg100 mg at weeks 0, 2, and 4, followed by 50 mg every 2 weeks
    20 kg to less than 40 kg200 mg at weeks 0, 2, and 4, followed by 100 mg every 2 weeks
    At least 40 kg400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks
    Juvenile idiopathic arthritis dosing
    Weight band10 kg to less than 20 kg
    Induction100 mg at weeks 0, 2, and 4
    Maintenance50 mg every 2 weeks
    Juvenile idiopathic arthritis dosing
    Weight band20 kg to less than 40 kg
    Induction200 mg at weeks 0, 2, and 4
    Maintenance100 mg every 2 weeks
    Juvenile idiopathic arthritis dosing
    Weight bandAt least 40 kg
    Induction400 mg at weeks 0, 2, and 4
    Maintenance200 mg every 2 weeks
    Dosage requirementPrescription-strength dosages
    Juvenile idiopathic arthritis weight bands
    Lower weight band10 kg to less than 20 kg
    Middle weight band20 kg to less than 40 kg
    Upper weight bandGreater than or equal to 40 kg
    Crohn's disease activity
    Minimum CDAI220 points
    Maximum CDAI450 points
    Disease activity categoryModerately to severely active Crohn's disease
    Crohn's disease clinical response
    Required reductionAt least 100 points
    MeasureCrohn's Disease Activity Index (CDAI)
    ComparisonReduction from baseline
    Crohn's disease clinical remission
    Remission thresholdAbsolute CDAI score of 150 points or lower
    MeasureCrohn's Disease Activity Index (CDAI)
    Assessment typeAbsolute score
    Plaque psoriasis response
    Response measurePsoriasis Area and Severity Index (PASI)
    Response thresholdPASI 75
    MeaningAt least a 75% improvement in PASI
    Prior Authorization

    Juvenile Idiopathic Arthritis Authorization

    Prior authorization is required for requests for certolizumab pegol for active polyarticular juvenile idiopathic arthritis.

    • Document the diagnosis, applicable selection criteria, and requested weight-based dose.

    Unsupported block type: prior_auth

    Step Therapy

    Crohn's Conventional-Therapy Failure

    For Crohn's disease, document failure of conventional therapy before requesting initial Cimzia authorization, unless the therapies are expected to be ineffective or cause an adverse reaction.

    • Examples include corticosteroids, 6-mercaptopurine (6-MP), and azathioprine.
    Step Therapy

    Traditional DMARD Failure

    For rheumatoid arthritis or psoriatic arthritis, document failure of one or more traditional DMARDs unless there is clinical evidence or patient history showing that the therapy would be ineffective or cause an adverse reaction.

    • Methotrexate is an example of a traditional DMARD.
    Step Therapy

    Psoriatic Arthritis DMARD Trial

    For active psoriatic arthritis, document a failed trial of one or more traditional DMARDs before initial treatment with Cimzia, unless an exception applies.

    • Methotrexate is an example of a qualifying traditional DMARD.
    Step Therapy

    Ankylosing Spondylitis NSAID Trial

    For active ankylosing spondylitis, document failure of NSAID treatment unless there is clinical evidence or patient history indicating that NSAIDs would be ineffective or cause an adverse reaction.

    • The request must otherwise meet the applicable diagnosis, testing, dose, and non-combination criteria.
    Step Therapy

    Phototherapy or Systemic Therapy Trial

    For moderate to severe plaque psoriasis, document candidacy for phototherapy or systemic therapy and failure to respond to an adequate trial of a qualifying modality, unless an exception applies.

    • Ultraviolet B.
    • Psoralen plus ultraviolet A.
    • Systemic therapy such as methotrexate, cyclosporine, or acitretin.
    Step Therapy

    Axial Spondyloarthritis NSAID Trial

    For active non-radiographic axial spondyloarthritis, document failure of at least two months of continuous treatment with at least two different oral NSAIDs at prescription-strength dosages, unless an exception applies.

    • The diagnosis must be confirmed by sacroiliitis on MRI.
    Step Therapy

    Juvenile Idiopathic Arthritis DMARD Trial

    For polyarticular juvenile idiopathic arthritis, document failure of one or more traditional DMARDs unless there is clinical evidence or patient history indicating that the therapy would be ineffective or cause an adverse reaction.

    • Methotrexate is an example of a qualifying traditional DMARD.
    Documentation Required

    Weight and Dose Documentation

    Document the juvenile idiopathic arthritis patient's weight and requested dose because authorization is limited to the applicable weight-based regimen.

    • 10 kg to less than 20 kg: no more than 100 mg at weeks 0, 2, and 4, then 50 mg every 2 weeks.
    • 20 kg to less than 40 kg: no more than 200 mg at weeks 0, 2, and 4, then 100 mg every 2 weeks.
    • At least 40 kg: no more than 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks.
    Step Therapy

    Two Oral NSAID Trials

    Document at least two different oral NSAID trials for non-radiographic axial spondyloarthritis.

    • Trials must total at least two months of current continuous therapy.
    • Use prescription-strength dosages.
    Step Therapy

    Phototherapy or Systemic Therapy Documentation

    For plaque psoriasis, document a failed adequate trial of phototherapy or systemic therapy before requesting Cimzia.

    • Qualifying phototherapy includes ultraviolet B or psoralen plus ultraviolet A.
    • Qualifying systemic therapy includes methotrexate, cyclosporine, or acitretin.
    Documentation Required

    Initial Clinical Documentation

    Initial requests should include the clinical information needed to establish eligibility for the applicable indication.

    • Patient age, when applicable.
    • Diagnosis and disease activity or severity.
    • Prior treatment failures and relevant contraindication or adverse-reaction history.
    • Negative TB testing before treatment.
    • Requested dose and regimen.
    Documentation Required

    Continuation Documentation

    Continuation requests should document the authorization history, beneficial response from baseline, ongoing dose, and continued compliance with the applicable criteria.

    • Include the plan's initial authorization or authorization for an active course from a previous health plan.
    • Describe objective or clinical improvement from baseline.
    • Confirm the requested dose remains within policy limits.
    Billing Rule

    Product and Benefit Documentation

    Document that the request is for the lyophilized single-dose vial under the medical benefit.

    • The authorization does not apply to the non-lyophilized prefilled syringe.
    • If granted, authorization is limited to the medical benefit.
    Prior Authorization

    Continuation Authorization and Response

    Continuation authorization requires documentation of an authorized initial or transferred course and a beneficial clinical response from baseline.

    • Response may be shown through objective measures, clinical signs and symptoms, functional improvement, or reduced medication use, as applicable to the indication.
    • The requested regimen must remain within the indication-specific dose limit.
    Documentation Required

    Initial Documentation by Covered Indication

    For initial requests, document the indication-specific clinical facts supporting coverage.

    • Rheumatoid arthritis: age 18 or older and moderately to severely active disease.
    • Psoriatic arthritis: age 18 or older and active disease.
    • Ankylosing spondylitis: age 18 or older and active disease.
    • Plaque psoriasis: moderate to severe disease with qualifying body-surface-area or sensitive-area involvement.
    • Non-radiographic axial spondyloarthritis: active disease with MRI-confirmed sacroiliitis.
    • Polyarticular juvenile idiopathic arthritis: active disease or diagnosis as specified by the policy.
    Documentation Required

    Non-Radiographic Axial Spondyloarthritis Records

    For non-radiographic axial spondyloarthritis, include records confirming active disease with sacroiliitis on MRI and failure of the required NSAID therapy.

    • Document at least two months of continuous treatment with at least two different oral NSAIDs at prescription strength.
    Documentation Required

    Plaque Psoriasis Treatment History

    For plaque psoriasis, document treatment history and disease extent supporting eligibility.

    • Show moderate to severe plaque psoriasis.
    • Document greater than 10% body-surface-area involvement, or 10% or less involving sensitive or functionally significant areas such as the palms, soles, head/neck, or genitalia.
    • Include failed adequate phototherapy or systemic therapy when applicable.
    Documentation Required

    Juvenile Idiopathic Arthritis Records

    For juvenile idiopathic arthritis, submit records showing the qualifying diagnosis, active disease, prior DMARD history, TB testing, and applicable weight-based regimen.

    • Document active polyarticular juvenile idiopathic arthritis.
    • Document failure of one or more traditional DMARDs or the applicable exception.
    • Include the patient's weight and requested dose.
    Documentation Required

    Initial Juvenile Idiopathic Arthritis Documentation

    Initial juvenile idiopathic arthritis requests must include documentation of the diagnosis, traditional DMARD history, negative TB testing, absence of prohibited combination therapy, and the requested weight-based dose.

    • The request must meet one of the policy's weight-based dosing categories.
    Documentation Required

    Juvenile Idiopathic Arthritis Continuation Response

    For continuation juvenile idiopathic arthritis requests, document a beneficial response from baseline and the patient's current weight-based dose.

    • Response may include improved range of motion, reduced joint pain or tenderness, shorter morning stiffness, improved function, reduced corticosteroid dosage, or improved inflammatory markers.
    • The requested dose must remain within the applicable weight category.
    Documentation Required

    Disease-Specific Treatment History

    Maintain disease-specific treatment-history records to support medical necessity for the requested indication.

    • Traditional DMARD failure for rheumatoid or psoriatic arthritis or juvenile idiopathic arthritis.
    • NSAID failure for ankylosing spondylitis or non-radiographic axial spondyloarthritis.
    • Qualifying phototherapy or systemic-therapy failure for plaque psoriasis.
    • For axial spondyloarthritis, at least two months of two different prescription-strength oral NSAIDs.
    Prior Authorization

    Transition of Ongoing Therapy

    When a member changes health plans during an ongoing Cimzia course, provide the previous plan's authorization documentation with the request.

    • Blue Advantage may honor the authorization for the same service under the same type of in-network benefit for a 90-day transition period.
    • The service must otherwise be covered under the Blue Advantage plan.
    Billing Rule

    Benefit, Medical-Necessity, and Formulation Restrictions

    Coverage is available only when the applicable benefit is present, medical-necessity criteria are met, and the request is for the covered formulation and benefit.

    • The policy does not authorize the non-lyophilized prefilled syringe.
    • An approved request is limited to the lyophilized single-dose vial under the medical benefit.
    Denial Risk

    Investigational Use Excluded

    Investigational or experimental use is excluded from coverage except as required or otherwise permitted under applicable Medicare rules.

    • Coverage is limited to routine services for Category A IDE studies and eligible devices and related services for Category B IDE studies when not supplied by the trial sponsor.
    Denial Risk

    Patient-Selection Criteria Not Met

    A request may be denied when required patient-selection criteria are not met or are not documented.

    • Applicable age, diagnosis, disease activity or severity, prior-treatment, TB-testing, dosing, and non-combination requirements must be satisfied.
    • Continuation requests must show authorization history and beneficial response from baseline.
    Denial Risk

    Prohibited Combination Therapy

    Cimzia is not medically necessary when used in combination with another biologic DMARD or with specified targeted drugs.

    • Prohibited examples include adalimumab, including biosimilars, and etanercept.
    • Other listed prohibited drugs include apremilast and tofacitinib, including Xeljanz/XR.
    Denial Risk

    Continuation Criteria Not Documented

    Continuation therapy may be denied when the required authorization history, beneficial response, or other continuation criteria are not documented.

    • Response must be demonstrated from the baseline before Cimzia therapy.
    • The requested dose and non-combination requirements must remain compliant.
    Denial Risk

    Juvenile Idiopathic Arthritis Criteria Not Met

    Juvenile idiopathic arthritis requests may be denied when the diagnosis, DMARD history, TB testing, weight-based selection criteria, dosing, or non-combination requirement is not met.

    • Continuation requests must also document a beneficial clinical response.
    Denial Risk

    Disease-Specific Criteria Not Met

    Disease-specific criteria not met under the applicable indication may result in a finding that Cimzia is not medically necessary.

    • Traditional DMARD failure for rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis.
    • NSAID failure for ankylosing spondylitis or non-radiographic axial spondyloarthritis.
    • Qualifying plaque-psoriasis extent and failed phototherapy or systemic therapy.
    • Required treatment history for the applicable disease state.
    Denial Risk

    No Beneficial Clinical Response

    Continued Cimzia use is not medically necessary when the patient has not experienced a beneficial clinical response from baseline.

    • Document objective or clinical improvement appropriate to the indication before requesting continuation.
    Denial Risk

    Unlisted Indication or Dosage

    Indications or dosages other than those listed in the policy are considered investigational and are not available for coverage.

    • Requests that do not meet the listed patient-selection criteria are investigational unless specifically identified as not medically necessary.
    • Federal and state law and contract terms take precedence over the medical policy.
    Crohn's disease
    Disease typeChronic autoimmune disease
    Anatomic scopeMay affect any portion of the gastrointestinal tract, most commonly the ileum
    Typical manifestationsIntestinal-wall thickening and deep ulcers; extraintestinal manifestations may also occur
    Rheumatoid arthritis
    Disease typeChronic autoimmune disease
    Primary effectInflammation of the joints and surrounding tissues
    Additional involvementMay affect other organs
    Psoriatic arthritis
    Disease typeInflammatory arthritis
    AssociationOften associated with psoriasis of the skin
    Typical first-line treatmentTraditional disease-modifying antirheumatic drugs, such as methotrexate
    Traditional disease-modifying antirheumatic drugs
    FunctionModify the immune system and slow the disease process
    ExampleMethotrexate
    Other listed examplesCyclosporine, sulfasalazine, mercaptopurine, and gold compounds
    Non-radiographic axial spondyloarthritis
    Disease typeInflammatory arthritis of the spine
    Imaging distinctionThe non-radiographic variety is not evident on plain radiography
    Diagnostic evidenceActive inflammation of the sacroiliac joints demonstrated by MRI
    Crohn's disease response and remission
    Clinical responseAt least a 100-point reduction in CDAI from baseline
    Clinical remissionAbsolute CDAI score of 150 points or lower
    Disease activity measureCrohn's Disease Activity Index (CDAI)
    Medically necessary
    Clinical judgmentCare a provider exercising prudent clinical judgment would provide to prevent, evaluate, diagnose, or treat illness, injury, disease, or symptoms
    Practice standardConsistent with nationally accepted standards of medical practice
    AppropriatenessClinically appropriate in type, frequency, extent, level of care, site, and duration, and effective for the patient's condition
    Cost and convenienceNot primarily for personal comfort or convenience and not more costly than an equally effective alternative